Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
Novartis earnings edge higher on Cosentyx, Entresto
01:29am, Tuesday, 26'th Apr 2022
Core operating income at Novartis edged 3% higher in the first quarter as sales growth from new drugs was partly offset by unfavourable currency effects.
Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug
02:17pm, Monday, 25'th Apr 2022
The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.
Here's 1 High-Yield Dividend Stock to Consider Buying
06:31am, Monday, 25'th Apr 2022
Big pharma company Novartis pays big dividends -- but there are other reasons for investors to buy its stock.
7 Potential Biotech Stocks Buyout Targets in 2022
08:10am, Thursday, 21'st Apr 2022
Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of bl
11 Incredible Blue-Chip Bargains For The Ultimate Sleep Well At Night Retirement Portfolio
03:40pm, Monday, 18'th Apr 2022 Seeking Alpha
LOW, MA, CL, NVS, ALIZY, CSL, GOOG, PPG, ENB, O, and UGI create a perfectly diversified Ultra SWAN portfolio. Read why here.
3 Fantastic Biotech Stocks to Buy in April
10:04am, Monday, 18'th Apr 2022 The Motley Fool
These stocks are bright spots in an overall dismal market for biotech stocks.
3 Fantastic Biotech Stocks to Buy in April
06:04am, Monday, 18'th Apr 2022
These stocks are bright spots in an overall dismal market for biotech stocks.
2 Unstoppable Green Flags for AbbVie
11:00am, Thursday, 14'th Apr 2022 The Motley Fool
There's a silver lining around an approaching dark cloud.
BioCardia (BCDA) Gains FDA Nod for ARDS Cell Therapy Study
02:25pm, Wednesday, 13'th Apr 2022 Zacks Investment Research
BioCardia (BCDA) gets FDA approval to start a phase I/II study to evaluate its allogenic stem cell therapy candidate, BCDA-04, in patients with ARDS due to COVID-19.
BeiGene (BGNE) Brukinsa Superior to Imbruvica in Leukemia Study
02:23pm, Tuesday, 12'th Apr 2022 Zacks Investment Research
BeiGene (BGNE) is comparing Brukinsa to AbbVie's Imbruvica as a treatment for R/R CLL or SLL. Brukinsa achieves superior ORR versus Imbruvica in a phase III study.
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Aeglea Shares Additional Phase 3 Data In Inherited Metabolic Disease
Aeglea BioTherapeutics Inc (NAS
Novartis to cut thousands of jobs in global revamp - paper
03:19am, Tuesday, 12'th Apr 2022
Swiss drugmaker Novartis will cut thousands of jobs worldwide as it combines its pharma and oncology businesses in a reorganisation announced last week, Swiss newspaper Tages-Anzeiger reported on Tues
3 Things About Pfizer That Smart Investors Know
03:07pm, Friday, 08'th Apr 2022 The Motley Fool
The next few years might get a little bumpy.
Pharma Stock Roundup: PFE to Buy RSV Drugmaker, FDA Updates for NVS, MRK and RHHBY
01:28pm, Friday, 08'th Apr 2022 Zacks Investment Research
Pfizer (PFE) announces plans to acquire ReViral for up to $525 million. Merck (MRK), Novartis (NVS) and Roche (RHHBY) provide FDA updates.
Regeneron (REGN), Sanofi's Dupixent Gets EU Nod for Asthma in Kids
06:55pm, Thursday, 07'th Apr 2022 Zacks Investment Research
Regeneron (REGN) and Sanofi's (SNY) Dupixent receives label expansion in the European Union for severe asthma with type 2 inflammation in children aged between 6 years and 11 years.
